Tiziana Life Sciences Ltd TLSA
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -16.83% | -16.83% | -25.99% | -25.99% | 51.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.82% | 23.82% | 28.63% | 28.63% | 41.17% |
| Operating Income | -23.82% | -23.82% | -28.63% | -28.63% | -41.17% |
| Income Before Tax | -119.94% | -119.94% | -46.01% | -46.01% | 29.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -119.94% | -119.94% | -77.54% | -77.54% | -21.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -119.94% | -119.94% | -77.54% | -77.54% | -21.01% |
| EBIT | -23.82% | -23.82% | -28.63% | -28.63% | -41.17% |
| EBITDA | -23.81% | -23.81% | -28.61% | -28.61% | -41.27% |
| EPS Basic | -100.83% | -100.83% | -63.30% | -63.30% | -6.64% |
| Normalized Basic EPS | -17.67% | -17.67% | -33.74% | -33.74% | -19.59% |
| EPS Diluted | -100.83% | -100.83% | -63.30% | -63.30% | -6.64% |
| Normalized Diluted EPS | -17.67% | -17.67% | -33.74% | -33.74% | -19.59% |
| Average Basic Shares Outstanding | 9.46% | 9.46% | 8.61% | 8.61% | 13.32% |
| Average Diluted Shares Outstanding | 9.46% | 9.46% | 8.61% | 8.61% | 13.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |